ArticleCureus2026
Seizures and Hyperleukocytosis Revealing New-Onset Acute Myeloid Leukemia During Acute COVID-19 Infection.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) with hyperleukocytosis is a hematologic emergency associated with high early mortality. Viral infections, including SARS-CoV-2, have been proposed as potential factors that may unmask previously undiagnosed leukemia or accelerate disease progression in predisposed individuals. We report the case of a previously healthy 61-year-old man who presented after recent travel with progressive fatigue, dizziness, fever, and multiple generalized seizures. Initial evaluation revealed COVID-19 infection with profound cytopenias and hyperleukocytosis, including a white blood cell (WBC) count of 132.9 × 10⁹/L, hemoglobin of 5.4 g/dL, and platelets of 11 × 10⁹/L. Peripheral smear demonstrated 36%-40% circulating myeloblasts with Auer rods, consistent with AML. Neuroimaging showed no intracranial hemorrhage. Laboratory evaluation revealed hyperuricemia, markedly elevated lactate dehydrogenase, hyperlactatemia (6.5 mmol/L), and acute kidney injury, concerning for early tumor lysis physiology. The patient was admitted to the intensive care unit and treated with hydroxyurea for cytoreduction, tumor lysis prophylaxis with allopurinol, transfusion support, and COVID-19-directed therapy. His leukocyte count decreased from 132.9 × 10⁹/L to 32.5 × 10⁹/L within 72 hours, with clinical stabilization. After initial cytoreduction and metabolic improvement, he was transferred to a tertiary oncology center for definitive induction therapy. This case raises the possibility that COVID-19-associated immune dysregulation may contribute to the clinical presentation of previously undiagnosed leukemia and underscores the importance of rapid cytoreduction, tumor lysis prevention, and multidisciplinary management in patients presenting with hyperleukocytic AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.